Literature DB >> 15191993

Hypocalcaemia after intravenous bisphosphonate: adjuvant bisphosphonate is not currently accepted practice.

Carlo Palmieri, Tony Dhillon, Charles Coombes, David Vigushin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15191993      PMCID： PMC421835          DOI： 10.1136/bmj.328.7453.1439-b

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Severe hypocalcaemia after being given intravenous bisphosphonate.

Authors:  Rajesh Peter; Vinita Mishra; William D Fraser
Journal:  BMJ       Date:  2004-02-07

2.  Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.

Authors:  T Saarto; C Blomqvist; P Virkkunen; I Elomaa
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

Review 3.  The anti-tumor potential of zoledronic acid.

Authors:  P Croucher; S Jagdev; R Coleman
Journal:  Breast       Date:  2003-08       Impact factor: 4.380

4.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.

Authors:  Trevor Powles; Sandy Paterson; John A Kanis; Eugene McCloskey; Sue Ashley; Alwynne Tidy; Kirsi Rosenqvist; Ian Smith; Lars Ottestad; Sandra Legault; Marjo Pajunen; Auli Nevantaus; Esa Männistö; Anne Suovuori; Sari Atula; Jaakko Nevalainen; Liisa Pylkkänen
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.